tradingkey.logo
tradingkey.logo

Dianthus Therapeutics Inc

DNTH
43.770USD
+1.330+3.13%
終値 12/22, 16:00ET15分遅れの株価
1.88B時価総額
損失額直近12ヶ月PER

Dianthus Therapeutics Inc

43.770
+1.330+3.13%

詳細情報 Dianthus Therapeutics Inc 企業名

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Dianthus Therapeutics Incの企業情報

企業コードDNTH
会社名Dianthus Therapeutics Inc
上場日Jun 21, 2018
最高経営責任者「CEO」Garcia (Marino)
従業員数78
証券種類Ordinary Share
決算期末Jun 21
本社所在地7 Times Square
都市NEW YORK
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号10036
電話番号19299994055
ウェブサイトhttps://dianthustx.com/
企業コードDNTH
上場日Jun 21, 2018
最高経営責任者「CEO」Garcia (Marino)

Dianthus Therapeutics Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Simrat Randhawa, M.D.
Dr. Simrat Randhawa, M.D.
Chief Medical Officer
Chief Medical Officer
4.00K
--
Dr. Simon Read, Ph.D.
Dr. Simon Read, Ph.D.
Independent Director
Independent Director
--
--
Ms. Anne McGeorge
Ms. Anne McGeorge
Independent Director
Independent Director
--
--
Mr. Sujay Kango
Mr. Sujay Kango
Independent Director
Independent Director
--
--
Mr. Marino Garcia
Mr. Marino Garcia
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
--
--
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
--
--
Mr. John C. King
Mr. John C. King
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Ryan Savitz
Mr. Ryan Savitz
Chief Financial Officer, Chief Business Officer Treasurer
Chief Financial Officer, Chief Business Officer Treasurer
--
--
Mr. Adam M. Veness, Esq., J.D.
Mr. Adam M. Veness, Esq., J.D.
Senior Vice President, General Counsel, Company Secretary
Senior Vice President, General Counsel, Company Secretary
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Simrat Randhawa, M.D.
Dr. Simrat Randhawa, M.D.
Chief Medical Officer
Chief Medical Officer
4.00K
--
Dr. Simon Read, Ph.D.
Dr. Simon Read, Ph.D.
Independent Director
Independent Director
--
--
Ms. Anne McGeorge
Ms. Anne McGeorge
Independent Director
Independent Director
--
--
Mr. Sujay Kango
Mr. Sujay Kango
Independent Director
Independent Director
--
--
Mr. Marino Garcia
Mr. Marino Garcia
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
--
--

収益内訳

会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。

株主

更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
Fidelity Management & Research Company LLC
13.73%
RA Capital Management, LP
6.69%
Wellington Management Company, LLP
6.01%
Octagon Capital Advisors LP
5.64%
Fairmount Funds Management LLC
4.98%
他の
62.95%
株主統計
株主統計
比率
Fidelity Management & Research Company LLC
13.73%
RA Capital Management, LP
6.69%
Wellington Management Company, LLP
6.01%
Octagon Capital Advisors LP
5.64%
Fairmount Funds Management LLC
4.98%
他の
62.95%
種類
株主統計
比率
Hedge Fund
37.11%
Investment Advisor
32.34%
Investment Advisor/Hedge Fund
20.66%
Venture Capital
13.11%
Corporation
5.89%
Research Firm
1.65%
Private Equity
0.29%
Pension Fund
0.08%
Bank and Trust
0.05%

機関投資家保有株

更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
262
46.28M
100.64%
-1.09M
2025Q3
262
47.37M
104.73%
+7.65M
2025Q2
229
39.60M
125.17%
+1.05M
2025Q1
225
38.14M
115.10%
+1.17M
2024Q4
221
35.31M
117.69%
+2.28M
2024Q3
220
31.55M
110.44%
+1.66M
2024Q2
202
29.76M
95.11%
+3.64M
2024Q1
206
26.10M
70.38%
+5.44M
2023Q4
202
10.31M
84.85%
+214.29K
2023Q3
217
10.09M
29.94%
+8.27M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Fidelity Management & Research Company LLC
4.45M
11.18%
+73.92K
+1.69%
Jun 30, 2025
RA Capital Management, LP
2.87M
7.2%
--
--
Jun 30, 2025
Octagon Capital Advisors LP
2.34M
5.88%
--
--
Jun 30, 2025
Fairmount Funds Management LLC
3.31M
8.31%
+600.00K
+22.16%
Sep 11, 2025
Avidity Partners Management LP
1.74M
4.38%
+22.00K
+1.28%
Jun 30, 2025
Point72 Asset Management, L.P.
1.39M
3.5%
-501.79K
-26.49%
Jun 30, 2025
TCG Crossover Management, LLC
1.50M
3.77%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.45M
3.63%
+337.21K
+30.41%
Jun 30, 2025
Tellus Bioventures LLC
1.44M
3.61%
--
--
Mar 31, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares Neuroscience and Healthcare ETF
1.72%
Virtus LifeSci Biotech Clinical Trials ETF
1.23%
Invesco Dorsey Wright Healthcare Momentum ETF
0.6%
ALPS Medical Breakthroughs ETF
0.47%
State Street SPDR S&P Biotech ETF
0.15%
Avantis US Small Cap Equity ETF
0.11%
iShares Micro-Cap ETF
0.11%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
Vanguard US Momentum Factor ETF
0.07%
iShares Russell 2000 Value ETF
0.04%
詳細を見る
iShares Neuroscience and Healthcare ETF
比率1.72%
Virtus LifeSci Biotech Clinical Trials ETF
比率1.23%
Invesco Dorsey Wright Healthcare Momentum ETF
比率0.6%
ALPS Medical Breakthroughs ETF
比率0.47%
State Street SPDR S&P Biotech ETF
比率0.15%
Avantis US Small Cap Equity ETF
比率0.11%
iShares Micro-Cap ETF
比率0.11%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.09%
Vanguard US Momentum Factor ETF
比率0.07%
iShares Russell 2000 Value ETF
比率0.04%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
日付
種類
比率
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1
Sep 11, 2023
Merger
16→1

よくある質問

Dianthus Therapeutics Incの上位5名の株主は誰ですか?

Dianthus Therapeutics Incの上位5名の株主は以下のとおりです。
Fidelity Management & Research Company LLCは4.45M株を保有しており、これは全体の11.18%に相当します。
RA Capital Management, LPは2.87M株を保有しており、これは全体の7.20%に相当します。
Octagon Capital Advisors LPは2.34M株を保有しており、これは全体の5.88%に相当します。
Fairmount Funds Management LLCは3.31M株を保有しており、これは全体の8.31%に相当します。
Avidity Partners Management LPは1.74M株を保有しており、これは全体の4.38%に相当します。

Dianthus Therapeutics Incの株主タイプ上位3種は何ですか?

Dianthus Therapeutics Incの株主タイプ上位3種は、
Fidelity Management & Research Company LLC
RA Capital Management, LP
Wellington Management Company, LLP

Dianthus Therapeutics Inc(DNTH)の株式を保有している機関の数はいくつですか?

2025Q4時点で、Dianthus Therapeutics Incの株式を保有している機関は262社あり、保有株式の総市場価値は約46.28Mで、全体の100.64%を占めています。2025Q3と比較して、機関の持ち株は-4.10%増加しています。

Dianthus Therapeutics Incの最大の収益源は何ですか?

--において、--部門がDianthus Therapeutics Incにとって最大の収益を生み出しており、その金額は--で、全収益の--%を占めています。
KeyAI